Product Images Aripiprazole

Each tablet contains 10 mg of aripiprazole USP. This medication is used as per the instructions provided in the package insert. It is recommended to store the tablets in tightly closed containers, at a temperature of 20°C to 40°C. These Tablets, USP are manufactured by XCCare Pharmaceuticals, Inc. The tablets are produced by Ascent Pharmaceuticals, Inc. at their Central Islip facility.*

This is a description of a medication called Aripiprazole Tablets, USP, manufactured by XLCare Pharmaceutical, Inc. The tablets come in a bottle of 500, with each containing 15 mg of aripiprazole. The dosage information can be found in the package insert. The tablets should be stored in tightly closed containers at room temperature. The manufacturer is Ascent Pharmaceuticals, Inc. The information on this medication is intended for pharmacists and patients.*

XLcare Pharmaceuticals, Inc. presents their Aripiprazole Tablets, USP each containing 2mg of arpiprazole USP. The tablets come in packs of 500 and users should refer to the package insert for information on dosage. Tablets must be stored in containers tightly closed at 20° to 25°C (68 o 77°F) [see USP Controlled Room Temperature]. These tablets are manufactured by Ascent Pharmaceuticals, Inc. and distributed by XLCare Pharmaceuticals, Inc. at Lawrenceville, GA 30046. The last revision of the packaging was made in January 2021.*

The text describes a prescription medication called Aripiprazole Tablets, USP, with 20mg of Aripiprazole per tablet. The medication is dispensed by a pharmacist and is only available with a prescription. The usual dosage and prescribing information are included in the package insert. The medication should be stored in tightly closed containers at room temperature. It is manufactured by Ascent Pharmaceuticals, Inc. and distributed by XLCare Pharmaceutical, Inc. at their location in Lawrenceville, GA.*

Xicare Aripiprazole Tablets, USP containing 30mg of aripiprazole per tablet. This medication is only available with a prescription and the usual dosage should be followed, as outlined in the package insert. The tablets should be stored in a tightly closed container within the temperature range of 20-25°C (68-77°F) as per USP Controlled Room Temperature standards. Manufactured by XLCare Pharmaceutical Inc. and Ascent Pharmaceuticals Inc, this medication is dispensed by a pharmacist and supplied in packs of 500 tablets.*

Xlcare is a pharmaceutical tablet that contains 5mg of arpiprazole USP. The usual dosage is provided in the package insert. XLCare Pharmaceuticals manufactures the tablets which come in 500 pieces per container. It is manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY. The tablets should be stored in closed containers at a temperature of 20° Celsius.*

The text describes the effect of various drugs on Aripiprazole, including CYP3A4 inhibitors, CYP3A4 inducers, gastric acid blockers, valproate, and lorazepam. The table shows fold change and 90% of Aripiprazole PK, AUC, and Cmax due to the interaction of the drugs.*

This appears to be a chart or table showing the effect of certain drugs on aripiprazole, with different drugs listed in the left column and a range of values in the right column. It is not clear what the values pertain to, but it may be some measure of relative effect or interaction with aripiprazole.*

This appears to be a table containing information related to pharmacokinetics and pharmacodynamics of a certain drug for different demographic and health groups. The table includes information on the effect of CYP2D6 status, gender, age, and hepatic and renal impairment on the drug's PK properties like AUC and Cmax. Additionally, the table includes data related to Arpiprazole Fold Change and 90% CI, but no further context is given to understand what this represents.*

This text seems to be presenting the results of a study on the effects of dehyio-arpiprazole on metabolism and possible differences between genders, liver impairment, and renal impairment. The study showed information about the concentration of dehyio-arpiprazole in the bloodstream (Cmax) in different scenarios such as moderate or severe liver or renal impairment, as well as its relation to a reference. However, the text lacks context and it is not clear what the purpose of this study was or what implications these results may have.*

Not available.*

This appears to be a chart showing the comparison of relapse rates between subjects taking a drug called Arpiprazole and a control group taking a placebo. The chart displays the proportion of subjects who experienced relapse over a period of time, as well as the number of subjects at risk at each time point. The chart shows that the group taking Arpiprazole had lower relapse rates compared to the placebo group.*